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ㅋ
Cyclic vomiting syndrome (CVS) is a disorder characterized by recurrent episodes of incapacitating nausea and vomiting inter-
spersed with symptom free periods. Common triggers of cyclic vomiting include noxious stress, excitement, fatigue and men-
strual period. Here, we report a case of cyclic vomiting syndrome in adult patient characterized by stereotypical vomiting at-
tack, occurring in every menstruation period. Recurrent vomiting episodes began 6 years ago and we treated this patient with 
subcutaneous injection of goserelin, a gonadotropin-releasing hormone analogue (GnRHa) and oral estrogen. After 4 months 
of therapy, she was symptom free for the following 5 years, even with the resumed normal menstruation. Recurrence of vom-
iting attack with same pattern occurred 1 month before readmission. Treatment with intravenous lorazepam aborted vomiting, 
but could not prevent recurrences of vomiting and epigastric pain. We treated the patient with GnRHa and oral estradiol 
again which effectively prevented recurrence of the symptoms.
(J Neurogastroenterol Motil 2010;16:77-82)
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Introduction
Cyclic vomiting syndrome (CVS) is a relatively rare disorder 
characterized by recurrent episodes of severe nausea and vomit-
ing interspersed with symptom free periods. CVS remains as a 
clinical diagnosis which is based on three main criteria: stereo-
typical episodes of vomiting regarding acute onset and duration 
(＜ 1 week), three or more discrete vomiting episodes in the pre-
vious year and absence of nausea and vomiting between 
episodes.
1-3 It was initially described in children, but could occur 
in any age groups. Recent studies have demonstrated that it is in-
creasingly recognized as a cause of nausea and vomiting in adults 
and is highly disabling.
4,5 CVS is a heterogeneous syndrome 
whose etiology is still unclear. Triggering factors of acute emetic 
episodes are similar in adults and children with CVS which in-
clude infections (e.g., chronic sinusitis, upper respiratory in-
fections), emotional and psychological stress, motion sickness, Young Kook Shin, et al
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Figure 1. Pedigree of the patient’s family. In this pedigree, one patient
with cyclic vomiting syndrome (solid circle) and her younger
sister who had migraine headache (arrow) were detected.
lack of sleep, physical exhaustion and certain food products (e.g., 
chocolate, cheese, and monosodium glutamate).
6 In some wom-
en, episodes are triggered by menstruation in which oral contra-
ceptive pill could help to prevent symptoms.
1,6 Here we report a 
case of adult woman who had menstruation related cyclic vomit-
ing in whom GnRHa successfully prevented recurrence of the 
symptoms.
Case Report
A 23-year-old woman visited our emergency department for 
recurrent vomiting and epigastric pain that had developed 2 days 
ago. Six years ago, she experienced acute onset of vomiting and 
severe epigastric pain for the first time. After then, she had suf-
fered from recurrent, stereotypic episodes of incapacitating nau-
sea and vomiting, separated by intervals of symptom-free periods. 
Her symptoms occurred with the onset of menstrual period and 
lasted for 7-10 days. Recurrent vomiting, usually beginning in 
the late night, occurred 30-50 episodes per day and was usually 
associated with severe epigastric pain. After the end of menstrual 
period, the symptoms resolved spontaneously. Past medical and 
surgical history were unremarkable. The age of menarche was 13. 
Duration of menstrual flow was 7-10 days and amount of men-
strual flow was medium. Menstrual cycle was regular and mean 
duration was 30 days. She had not taken any medication. Her 
younger sister suffered from migraine with aura (Fig. 1). Physi-
cal examination, laboratory test, endoscopic examination and 
evaluation by gynecologist revealed no causative explanation for 
her symptoms. Management with proton pump inhibitor, an-
algesics, antiemetics or prokinetics did not affect the duration and 
severity of symptom episode. For management of dysmenorrhea, 
two monthly cycles of estrogen-progestin hormonal contra-
ceptives were administered, but it did not prevent recurrence of 
the symptoms. In order to induce amenorrhea, we treated her 
with subcutaneous injection of GnRHa (goserelin, 3.6 mg/month) 
and oral estrogen (premarin
Ⓡ, 0.625 mg/day) for 4 months. After 
then, menstruation disappeared for 6 months and she had experi-
enced 5 years of symptom-free period, even with the resumed 
normal menstruation. For the past 3 months before readmission, 
she had experienced anxiety and stress due to an examination. 
Recurrence of vomiting attack with same pattern occurred 1 
month before readmission which required hospitalization for in-
travenous hydration and symptom reduction. Treatment with in-
travenous lorazepam aborted symptoms of emetic phase. But, tri-
als of fluoxetine, a selective serotonin reuptake inhibitors (SSRI), 
could not prevent recurrence of the symptoms on the next men-
strual period. Upon admission, she had frequent nausea, vomit-
ing and severe epigastric pain, especially at late night and early 
morning. On physical examination, patient’s vital signs were sta-
ble and significant orthostatic change was not seen. The abdomen 
was soft, non-distended with normal bowel sound, but epigastric 
tenderness was noted. Neurological findings were unremarkable. 
Laboratory evaluation revealed white bood cell of 8,900/mm
3, he-
moglobin 12.8 g/dL, platelet 458,000/mm
3, serum sodium 139 
mEq/L, serum potassium 3.9 mEq/L, BUN 20 mg/dL, serum 
creatinine 0.8 mg/dL, aspartate aminotransferase 16 IU/L, ala-
nine aminotransferase 28 IU/L, total protein 8.1 g/dL, albumin 
4.7 g/dL, TSH 2.34 IU/mL, and free T4 1.21 IU/mL. Urinary 
pregnancy testing was negative. An extensive gastrointestinal 
workup including upper gastrointestinal endoscopy, upper gas-
trointestinal series with barium, abdomino-pelvic CT scans, elec-
trogastrogram (EGG) and gastric emptying scintiscans with 
99mTc-DTPA were done. Some of these studies were performed 
while the patient was symptomatic. EGG and gastric emptying 
scintiscans were performed just after improvement of symptoms 
and discontinuation of any prokinetic agent. Upper GI endos-
copy showed tongue-like mucosal projection just above the 
esophagogastric junction (Fig. 2). Upper GI series and abdomi-
no-pelvic CT scans identified no abnormality. EGG showed nor-
mally increased total power at post-prandial period and no brady-
gastria or tachygastria was identified (Fig. 3). Gastric emptying 
scintiscans demonstrated delayed gastric emptying. Half empty-
ing time (T1/2) was 107 minutes and percentage retained at 4 
hours was 22% (Fig. 4). Management with intravenous hydra-
tion, antiemetics and lorazepam reduced severity and duration of 
the symptoms. After then, we treated her with subcutaneous in-Cyclic Vomiting Syndrome Responding to Ganadotropin-Releasing Hormone Analogue
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Figure 2. Upper GI endoscopic find-
ings showing tongue-like mu-
cosal projection just above 
the esophagogastric junction 
(A). Neither mucosal abnor-
mality nor luminal narrowing
is identified in the stomach 
(B-D).
jections of GnRHa (goserelin 3.6 mg/month or leuprolide 3.75 
mg/month) and oral estradiol (2 mg/day) for 3 months and the 
patient showed no recurrence of the symptoms for 6 months dur-
ing follow-up visits.
Discussion
CVS is a rare disorder diagnosed primarily in children and 
frequently misdiagnosed as acute gastroenteritis, gastroesopha-
geal reflux disease, pancreatitis or eating disorders.
2,7,8 Patients 
with CVS typically present with recurrent stereotypic episodes of 
nausea and vomiting lasting hours or days and each episode is 
separated by symptom free-intervals, which last weeks or months. 
Vomiting typically begins during the night or early morning and 
peaks in the first hour, occurring up to 13 times per hour.
3
Classically perceived as a pediatric disorder, CVS is being 
recognized increasingly in adults. Cyclic vomiting episodes in 
children cease spontaneously before puberty in most cases, but 
persistence through to adult life is well recognized. Adults with 
CVS can occur at any age, with an average age of onset of 21-35 
years in limited case series. Although the clinical features in each 
age groups are similar,
9 a few differences in symptom profile, 
pathogenesis and associated comorbidities between adults and 
children have been observed.
1 Median interval of episode is 4 
weeks in children and 3 months in adults.
10 Nausea or dyspepsia 
between episodes is more common in adults. Delays in diagnosis 
appear less frequently in pediatric patients (1.9 years) than in 
adults (7.9 years).
11
The pathophysiology of CVS has not been established, and 
recent investigations suggest that several factors, including meta-
bolic disorders, migraines, autonomic dysregulation, hypothala-
mic-pituitary-adrenal axis defects, a tendency for anxiety and 
chronic cannabis use could precipitate CVS in some cases. 
68-80% of CVS attacks have associated trigger mechanisms such 
as infection, psychological stress, physical stress, inadequate 
sleep, diet, motion sickness and onset of menses.
6 Up to 13% of 
postmenarchial girls develop CVS at the onset of menstrual peri-
od (named catamenial CVS).
12 We suggest that anticipatory anxi-
ety and stress for an examination and menstruation together con-
tributed to the triggering factors of vomiting attacks in our case. 5 
years of symptom-free period may be related with period of re-
duced anxiety and stress.Young Kook Shin, et al
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Figure 3. Electrogastrogram findings showing normally increased total power at postprandial period (A, B). Neither bradygastria nor tachygastria is
identified (C, D).
CVS remains a diagnosis based upon the history and ex-
clusion of alternative diagnoses. Rome III criteria include the 
stereotypical episodes of vomiting, three or more discrete epi-
sodes, and symptom free periods. The criteria should be fulfilled 
for the last three months with symptom onset at least six months 
before diagnosis. Supportive criteria includes history or family 
history of migraine headaches.
3 The recurrent vomiting attacks 
and symptom-free interval of our case met the consensus criteria 
of CVS and family history revealed migraine headache of the 
sister. Duration of episode in our case is not consistent with Rome 
III criteria. However, longer duration of episodes (＞ 1 week) 
has been found in some adult patients with cyclic vomiting 
syndrome.
12
Differential diagnosis of CVS is very broad and it is im-
portant to exclude other gastrointestinal disorders and extra-in-
testinal disorders, including metabolic and central nervous sys-
tem diseases, renal disorders, and psychogenic vomiting. The ex-
tent of diagnostic evaluation and the role for the use of empiric 
therapy for migraine in patients with CVS remains undefined. 
Diagnostic approach to exclude other disorders with recurrent 
vomiting includes biochemical testing for electrolyte abnormal-
ities, serum calcium, thyroid function tests and liver function 
tests. An upper GI series with small bowel follow-through X-ray, 
CT/MRI of the head, and endoscopy can be performed in be-
tween episodes.
7,8,13 Because the vomiting attacks only occurred 
at the onset of menstruation, we suspected dysmenorrhea as a 
cause of symptoms. But, neither the typical manifestations of dys-
menorrhea were identified nor the treatment for it controlled the 
symptoms.
Gastric emptying scintiscans have been investigated in adult 
patients with CVS, primarily during asymptomatic periods in be-
tween emetic episodes. Rapid gastric emptying at baseline, which 
may be related to autonomic dysfunction, or delayed gastric emp-
tying during episodes have been demonstrated in adults with 
CVS.
14,15 In our case, gastroparesis was initially considered as a 
cause of frequent vomiting episodes. But, trials with prokinetics 
including erythromycin, mosapride and antiemetics did not affect 
the duration and severity of symptom episode. Moreover, on-off 
symptom pattern with intervals of complete normality in between 
menstruation suggests uncertain association between vomiting 
episodes and gastroparesis.
No specific therapy has been proven to be effective for CVS 
in controlled trials. However, several empiric treatments have 
been effective in case series.
16 Life style changes, abortive treat-Cyclic Vomiting Syndrome Responding to Ganadotropin-Releasing Hormone Analogue
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Figure 4. Gastric emptying scintiscans 
showing delayed gastric em-
ptying (A-D). Half empty-
ing time (T1/2) is 107 mi-
nutes and the percentage 
retained at 4 hour is 22% (D).
ment, prophylactic therapy, and supportive care to ameliorate 
acute episodes are efficient treatments. Avoidance of potential 
triggers is helpful. Diabetes should be managed with strict glu-
cose control and episodes of hypoglycemia should be avoided. 
Treatments during the emetic phase consist of hydration, antie-
metic, antianxiety and/or analgesic medications. Supportive care 
with fluid replacement and electrolyte control is often necessary. 
A constant intravenous infusion of 5-HT3 antagonist, ondanse-
tron, has shown an efficacy of about 60% if given early in the 
vomiting attack.
17 If nausea persists, addition of lorazepam pro-
vides sedation that may lessen intractable nausea in some cases.
11 
In our case, repeated injections of lorazepam during the emetic 
phase reduced both nausea and vomiting. But, treatment with 
lorazepam and fluoxetine did not prevent recurrence of symp-
toms.
Some studies have investigated the drug therapy in prevent-
ing episodes of CVS and only a small number of maintenance 
therapies have so far been reported to be effective. Low-dose tri-
cyclic antidepressants, sumatriptan, and beta blockers (e.g., pro-
pranolol) have been found to be effective in prevention of 
episodes.
1,18 If psychiatric disorder is present, it should also be 
treated. If menstrual cycles trigger an attack, GnRHa injections 
or continuous birth control to block menses should be consi-
dered. Although low-dose estrogen oral contraceptives could 
help to prevent the vomiting attack in patients with menstruation- 
related CVS,
11 oral contraceptives can also exacerbate symptoms 
on the other hand.
16,19 Administration of GnRHa down-regu-
lates the pituitary-ovarian gonadal axis and reduces levels of the 
gonadotropin, luteinizing hormone and follicle-stimulating 
hormone.
20 GnRHa suppresses ovulation and is found to have 
benefits in the treatment of premenstrual syndrome. However, 
maximum treatment period is 6 months, and hormone replace-
ment therapy has to be given to prevent side effects.
21 We chose 
GnRHa and estrogen replacement therapy as the prophylactic 
therapeutic modality due to its efficacy in preventing vomiting at-
tack and a relatively short period of courses of therapy (e.g., 3 
months).
In conclusion, careful understanding of the history, symptom 
pattern and triggering factors should be obtained in patients with 
recurrent vomiting attacks. For women with menstruation-re-
lated CVS, we suggest that GnRHa is an effective therapeutic 
modality for preventing symptom episode.Young Kook Shin, et al
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